Page last updated: 2024-08-26

yttrium radioisotopes and Lassitude

yttrium radioisotopes has been researched along with Lassitude in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Fusco, F; Gibbs, P; Gray, AM; Love, S; Moschandreas, J; Sharma, RA; Van Hazel, G; Virdee, PS; Wasan, HS; Wolstenholme, J1
Fabregas, JC; Goodman, D; Hoffman, JE; Hosein, PJ; Koru-Sengul, T; Lossos, IS; Miao, F; Rosenblatt, JD; Serafini, AN; Stefanovic, A1
Ashoori, N; Haug, A; Hoffmann, RT; Jakobs, TF; Paprottka, PM; Raessler, F; Reiser, MF; Schmidt, GP; Sommer, WH; Trumm, CG1
Atassi, B; Benson, AB; Gates, VL; Gupta, R; Lewandowski, RJ; Memon, K; Miller, FH; Mulcahy, MF; Newman, S; Nikolaidis, P; Omary, RA; Riaz, A; Ryu, RK; Salem, R; Sato, KT; Yaghmai, V1

Trials

2 trial(s) available for yttrium radioisotopes and Lassitude

ArticleYear
Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancer.
    International journal of cancer, 2020, 08-15, Volume: 147, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colorectal Neoplasms; Fatigue; Female; Humans; Liver Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Surveys and Questionnaires; Vomiting; Yttrium Radioisotopes

2020
Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Fatigue; Female; Fever; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Radioimmunotherapy; Remission Induction; Thrombocytopenia; Treatment Outcome; Yttrium Radioisotopes

2015

Other Studies

2 other study(ies) available for yttrium radioisotopes and Lassitude

ArticleYear
Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
    Cardiovascular and interventional radiology, 2012, Volume: 35, Issue:2

    Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Digestive System Diseases; Embolization, Therapeutic; Fatigue; Female; Fever; Follow-Up Studies; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Radiation Dosage; Retrospective Studies; Yttrium Radioisotopes

2012
Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.
    International journal of radiation oncology, biology, physics, 2012, Jul-01, Volume: 83, Issue:3

    Topics: Abdominal Pain; Aged; Analysis of Variance; Diarrhea; Embolization, Therapeutic; Fatigue; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Nausea; Neuroendocrine Tumors; Retrospective Studies; Survival Rate; Treatment Outcome; Vomiting; Weight Loss; Yttrium Radioisotopes

2012